4.3 Article

Strong immunoexpression of dickkopf-1 is associated with response to bortezomib in multiple myeloma

Journal

LEUKEMIA & LYMPHOMA
Volume 59, Issue 11, Pages 2670-2678

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2018.1443331

Keywords

Multiple myeloma; bortezomib; dickkopf-1

Funding

  1. Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health Welfare [HI14C1967]

Ask authors/readers for more resources

The predictive significance of osteolysis-related proteins was evaluated in bortezomib-treated multiple myeloma. The clinicopathological characteristics were collected retrospectively. Immunohistochemistry was performed for analyzing receptor activator of NF-kappa B ligand (RANKL), osteoprotegerin (OPG), macrophage inflammatory protein 1 alpha (MIP1 alpha), and dickkopf-1 (DKK1) expression. Among clinicopatholgical characteristics, osteolytic lesion was associated with higher response to bortezomib treatment (79% vs. 46%). High DKK1 expression was significantly correlated with osteolytic lesion (p = .003), whereas RANKL, OPG, and MIP1 alpha were not. In high DKK1 expression, higher response to bortezomib was observed (84% vs. 44%). In multivariate analysis, high DKK1 expression was associated with better response to bortezomib (p = .005). Patients with high DKK1 expression had longer median progression-free survival (PFS) and overall survival (OS) after bortezomib treatment. In multivariate analysis, high DKK1 expression was an independent prognostic factor of favorable PFS (p = .027) and OS (p = .035). In multiple myeloma treated with bortezomib, expression status of DKK1 may be a useful predictive marker.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available